非感染性葡萄膜炎靶向免疫调节疗法综述
A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis.
作者信息
Sharma Srilakshmi M, Fu Dun Jack, Xue Kanmin
机构信息
Oxford University Hospitals NHS Foundation Trust, Oxford Eye Hospital, Oxford, UK.
Nuffield Laboratory of Ophthalmology, West Wing, John Radcliffe Hospital, University of Oxford, Oxford, UK.
出版信息
Ophthalmol Ther. 2018 Jun;7(1):1-17. doi: 10.1007/s40123-017-0115-5. Epub 2017 Nov 30.
Abstract
Systemic immunomodulatory therapies are the principal means of managing non-infectious uveitis. This review aims to explore the current landscape of systemic uveitis treatments, including biologic therapies and the advent of biosimilar therapies.
摘要
全身免疫调节疗法是治疗非感染性葡萄膜炎的主要手段。本综述旨在探讨全身葡萄膜炎治疗的现状，包括生物疗法以及生物类似药疗法的出现。
相似文献
1
A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis.
Ophthalmol Ther. 2018 Jun;7(1):1-17. doi: 10.1007/s40123-017-0115-5. Epub 2017 Nov 30.
2
Biologic agents in inflammatory eye disease.
J Ophthalmic Vis Res. 2011 Oct;6(4):309-16.
3
The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.
Paediatr Drugs. 2015 Aug;17(4):283-301. doi: 10.1007/s40272-015-0128-2.
4
Biologics in the treatment of uveitis.
Curr Opin Ophthalmol. 2007 Nov;18(6):481-6. doi: 10.1097/ICU.0b013e3282f03d42.
5
Expert opinion on the use of biological therapy in non-infectious uveitis.
Expert Opin Biol Ther. 2019 May;19(5):477-490. doi: 10.1080/14712598.2019.1595578. Epub 2019 Apr 16.
6
The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors.
Front Pharmacol. 2019 Dec 9;10:1468. doi: 10.3389/fphar.2019.01468. eCollection 2019.
7
Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile.
Curr Drug Saf. 2016;11(1):47-54. doi: 10.2174/1574886310666151014114925.
8
Biologic Therapies: Anti-Tumor Necrosis Factor-α, Anti-Interleukins, Rituximab and Others.
Dev Ophthalmol. 2016;55:252-64. doi: 10.1159/000431201. Epub 2015 Oct 26.
9
New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.
Semin Arthritis Rheum. 2019 Dec;49(3):438-445. doi: 10.1016/j.semarthrit.2019.06.004. Epub 2019 Jun 10.
10
IL-6 blockade in the management of non-infectious uveitis.
Clin Rheumatol. 2017 Jul;36(7):1459-1469. doi: 10.1007/s10067-017-3672-z. Epub 2017 May 20.
引用本文的文献
1
Biologics in ocular inflammatory diseases - Experience from a tertiary referral eye care center in South India.
Indian J Ophthalmol. 2025 Feb 1;73(2):267-272. doi: 10.4103/IJO.IJO_1126_24. Epub 2024 Sep 10.
2
Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis.
Sci Rep. 2024 Aug 28;14(1):20033. doi: 10.1038/s41598-024-68401-y.
3
Chronic Recurrent Multifocal Osteomyelitis (CRMO) and Juvenile Spondyloarthritis (JSpA): To What Extent Are They Related?
J Clin Med. 2023 Jan 5;12(2):453. doi: 10.3390/jcm12020453.
4
Pathogenesis and current therapies for non-infectious uveitis.
Clin Exp Med. 2023 Aug;23(4):1089-1106. doi: 10.1007/s10238-022-00954-6. Epub 2022 Nov 24.
5
Interleukins and cytokine biomarkers in uveitis.
Indian J Ophthalmol. 2020 Sep;68(9):1750-1763. doi: 10.4103/ijo.IJO_564_20.
6
New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview.
Front Pharmacol. 2020 May 8;11:655. doi: 10.3389/fphar.2020.00655. eCollection 2020.
7
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
Ann Rheum Dis. 2019 Sep;78(9):1167-1178. doi: 10.1136/annrheumdis-2019-215356. Epub 2019 Jul 5.
8
Dysbiosis in the Gut Bacterial Microbiome of Patients with Uveitis, an Inflammatory Disease of the Eye.
Indian J Microbiol. 2018 Dec;58(4):457-469. doi: 10.1007/s12088-018-0746-9. Epub 2018 Jun 4.
本文引用的文献
1
Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.
Am J Ophthalmol. 2017 Nov;183:71-80. doi: 10.1016/j.ajo.2017.08.019. Epub 2017 Sep 5.
2
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
Ann Rheum Dis. 2017 Oct;76(10):1679-1687. doi: 10.1136/annrheumdis-2016-210459. Epub 2017 Jun 5.
3
Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
JAMA. 2017 May 16;317(19):1993-2005. doi: 10.1001/jama.2017.5103.
4
Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation.
Jpn J Ophthalmol. 2017 Mar;61(2):169-178. doi: 10.1007/s10384-016-0490-9. Epub 2016 Dec 10.
5
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.
BioDrugs. 2016 Dec;30(6):525-570. doi: 10.1007/s40259-016-0201-6.
6
Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
Ophthalmology. 2016 Nov;123(11):2413-2423. doi: 10.1016/j.ophtha.2016.07.029. Epub 2016 Sep 28.
7
8
Adalimumab in Patients with Active Noninfectious Uveitis.
N Engl J Med. 2016 Sep 8;375(10):932-43. doi: 10.1056/NEJMoa1509852.
9
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16.
10
Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.
Semin Arthritis Rheum. 2016 Aug;46(1):95-101. doi: 10.1016/j.semarthrit.2016.03.002. Epub 2016 Mar 9.
Zotero 插件